Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07092059 · ClinicalTrials.gov registry record · NA
Smartphone Services for Stimulant Use Disorder
A NA study of Stimulant Use Disorder, sponsored by DynamiCare Health.
- Recruiting
- Registry status
- NA
- Development phase
- 270
- Enrollment target
- 1
- Study location
NCT07092059: Recruiting NA study of Stimulant Use Disorder, sponsored by DynamiCare Health.
NCT07092059 is a NA study of Stimulant Use Disorder that is actively recruiting participants, run by DynamiCare Health. The registered enrollment target is 270 participants, above the 181-participant average among 9 other Stimulant Use Disorder trials with a reported enrollment target (49% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07092059, a NA study of Stimulant Use Disorder, is actively recruiting participants, sponsored by DynamiCare Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 270 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is testing two approaches to treating Stimulant Use Disorder, or problems with cocaine, crack, methamphetamine, etc. Stimulant Use Disorder is a national epidemic in the U.S. but there is no FDA-approved medication to treat it. There is a behavioral approach that has been found to be the most effective treatment for Stimulant Use Disorder, but this study is testing whether this can be delivered by a smartphone service, remotely, such as at home.
Primary Outcome
We will measure if your saliva drug tests show any use of drugs.
Conditions Studied
Interventions
- DEVICE Smartphone digital therapeutic system
Study Locations (1)
Massachusetts
- This is an At-Home Study - no travel or on-site visits are needed at all; Main Office: 6 Liberty Sq, #2102 - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2025-06-24 |
| Est. Completion | 2027-08 |
| Phase | NA |
What NCT07092059 shows while recruiting
NCT07092059 is an interventional study that assigns participants to a tested intervention. The registered 270 participants enrollment target is mid-sized for trials with a published cap, above the 181-participant average among 9 other Stimulant Use Disorder trials with a reported enrollment target (49% higher).
The record links to 1 condition, with Stimulant Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Smartphone digital therapeutic system is the first listed.
NCT07092059 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07092059 about?
NCT07092059 is a clinical study titled "Smartphone Services for Stimulant Use Disorder". This study is testing two approaches to treating Stimulant Use Disorder, or problems with cocaine, crack, methamphetamine, etc. Stimulant Use Disorder is a national epidemic in the U.S. but there is no FDA-approved medication to treat it. There is a behavioral approach that has been found to be the ...
What is the current status of trial NCT07092059?
This trial is currently recruiting. It is a NA study. The enrollment target is 270 participants. The study started on 2025-06-24. Estimated completion is 2027-08.
What conditions does trial NCT07092059 study?
This clinical trial studies the following conditions: Stimulant Use Disorder.
What interventions are being tested in trial NCT07092059?
The interventions under investigation include: Smartphone digital therapeutic system (DEVICE).
Who is sponsoring clinical trial NCT07092059?
This trial is sponsored by DynamiCare Health, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07092059 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stimulant Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07092059's enrollment target sits among peer trials
270 4th of 9 higher than 6 of 9 other Stimulant Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stimulant Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
reSET for the Treatment of Stimulant Use in HIV Clinics: Care Optimization Supporting Treatment Adherence (COSTA)
RECRUITING · NA
-
Continuum of Care in Hospitalized Patients With Opioid/Stimulant Use Disorder and Infectious Complications From Drug Use
RECRUITING · NA
-
Addressing Risk Through Community Treatment for Infectious Disease and Opioid Use Disorder Now (ACTION) Among Justice-involved Populations
ACTIVE NOT RECRUITING · NA
-
Contingency Management for Opioid and Stimulant Use Disorders in Primary Care
ACTIVE NOT RECRUITING · NA
-
Orexin Receptor Antagonism and Sleep in Stimulant Use Disorder
RECRUITING · Phase 2
-
Optimizing Transcranial Magnetic Stimulation for Stimulant Use Disorder
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00801489 · 270 participants · Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- NCT04372485 · 270 participants · NA
Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents
- NCT04528446 · 270 participants
The Impact of Glomerular Disorders on Bone Quality and Strength
- NCT05215327 · 270 participants · Phase 2
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI